Cited by 1,012Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Open access

Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Restifo, Nicholas P., Haworth, Leah R., Levy, Catherine, Mavroukakis, Sharon A., Nichol, Geoff, Yellin, Michael J., Rosenberg, Steven A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.06.205PMC PMC1473965

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) in conjunction with peptide vaccination. We have now treated 56 patients to evaluate two different dose schedules of anti–CTLA-4 and to explore the relationship between autoimmunity and tumor regression. Patients and Methods: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study. All had Karnofsky performance status ≥ 60% with no prior history of autoimmunity. Twenty-nine patients received 3 mg/kg anti–CTLA-4 every 3 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 weeks. In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). Results: Two patients achieved a complete response (ongoing at 30 and 31 months, respectively) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, respectively), for an overall objective response rate of 13%. Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites. Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clinical response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008). There were no significant differences in response rate or toxicity between the two dose schedules. Conclusion: Administration of anti–CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.06.205

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,860
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097

Flagged first, then by citations

Show all 44 references

Sorted by citations

Items 501–600 of 1,000

Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang
Ernstoff, M. S., Crocenzi, T. S., Seigne, J. D., Crosby, N. A., Cole, B. F., Fisher, J. L., Uhlenhake, J. C., Mellinger, D., Foster, C., Farnham, C. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2064 · Cited by 29
Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma
Sammartino, C., Goodman, D., Flanagan, G. C., & Hill, P. A. (2009) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfp177 · Cited by 29
Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases
Qin, J., Upadhyay, V. A., Prabhakar, B. S., & Maker, A. V. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-70 · Cited by 29
Self-citation
Immune Regulatory Antibodies
Wolchok, J. D., Yang, A. S., & Weber, J. S. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3381 · Cited by 28
Reduced incidence of skin cancer in patients with alopecia areata: A retrospective cohort study
Mostaghimi, A., Qureshi, S., Joyce, C., Guo, Y., & Huang, K. P. (2016) · Cancer Epidemiology · doi:10.1016/j.canep.2016.02.009 · Cited by 28
Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
Soldatos, T. G., Dimitrakopoulou‐Strauss, A., Larribère, L., Hassel, J. C., & Sachpekidis, C. (2018) · Diagnostics · doi:10.3390/diagnostics8040076 · Cited by 29
Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis
Kono, M., Sakurai, T., Okamoto, K., Masaki, S., Nagai, T., Komeda, Y., Kamata, K., Minaga, K., Yamao, K., Takenaka, M., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.1981-18 · Cited by 28
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
Shah, N., Jacob, J. M., Househ, Z., Shiner, E. K., Baird, L., & Soudy, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0727-5 · Cited by 29
Dermatologic Adverse Events of Checkpoint Inhibitors: What an Oncologist Should Know
Habre, M., Habre, S. B., & Kourié, H. R. (2016) · Immunotherapy · doi:10.2217/imt-2016-0074 · Cited by 28
Treatment of hypertension in a managed care setting.
DiTusa, L., Luzier, A. B., Jarosz, D. E., Snyder, B. D., & Izzo, J. L. (2001) · PubMed · Cited by 28
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology
Martineau, R., Susini, S., & Marabelle, A. (2024) · Immunological Reviews · doi:10.1111/imr.13427 · Cited by 27
Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD‐1‐Antikörper beim metastasierten Melanom – ein Update
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 27
Multimodality imaging of endocrine immune related adverse events: a primer for radiologists
Alessandrino, F., Shah, H., & Ramaiya, N. H. (2018) · Clinical Imaging · doi:10.1016/j.clinimag.2017.12.014 · Cited by 27
Cancer immunotherapy for metastasis: past, present and future
Wang, X., Fan, S., Pan, H., Chen, W., & Wang, H. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely022 · Cited by 28
Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers
Yamamoto, A., Yano, Y., Ueda, Y., Yasutomi, E., Hatazawa, Y., Hayashi, H., Yoshida, R., Asaji, N., Shiomi, Y., Tobimatsu, K., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03448-8 · Cited by 28
Melanoma vaccines: The problems of local immunosuppression
Polak, M. E., Borthwick, N., Jager, M. J., & Cree, I. A. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.01.017 · Cited by 27
Responses to immune checkpoint inhibitors in nonagenarians
Johnpulle, R. A. N., Conry, R. M., Sosman, J. A., Puzanov, I. J., & Johnson, D. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1234572 · Cited by 27
Adjuvant Therapy of Melanoma
Shah, G., & Chapman, P. B. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e318074dfd4 · Cited by 27
The delicate balance of melanoma immunotherapy
Gyorki, D. E., Callahan, M. K., Wolchok, J. D., & Ariyan, C. E. (2013) · Clinical & Translational Immunology · doi:10.1038/cti.2013.5 · Cited by 26
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
Rossi, E., Sgambato, A., Chiara, G. D., Casaluce, F., Losanno, T., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133289 · Cited by 26
Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research
Kidwell, K., Postow, M. A., & Panageas, K. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1355 · Cited by 26
Glucocorticoids and immune checkpoint inhibitors in glioblastoma
Kelly, W., & Gilbert, M. R. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03439-2 · Cited by 26
Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up
Aamdal, E., Jacobsen, K. D., Straume, O., Kersten, C., Herlofsen, O., Karlsen, J., Hussain, I., Amundsen, A., Dalhaug, A., Nyakas, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33768 · Cited by 26
Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?
D'Arena, G. F., Simeon, V., D’Auria, F., Statuto, T., Sanzo, P. D., Martino, L. D., Marandino, A., Sangiorgio, M., Musto, P., & Feo, V. D. (2013) · Europe PMC (PubMed Central) · Cited by 26
Metastatic melanoma: the new era of targeted therapy
Guida, M., Pisconti, S., & Colucci, G. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645807 · Cited by 27
Anti–CTL-Associated Antigen 4: Are Regulatory T Cells a Target?
Gabriel, E. M., & Lattime, E. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2820 · Cited by 26
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
Gogas, H. J., Dafni, U. G., Koon, H. B., Spyropoulou‐Vlachou, M., Metaxas, Y., Buchbinder, E. I., Pectasides, E., Tsoutsos, D. A., Polyzos, A., Stratigos, A., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-108 · Cited by 26
Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events
Ihara, K. (2019) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.28.59 · Cited by 26
Current topics in melanoma
Wolchok, J. D., & Saenger, Y. M. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32801497c6 · Cited by 26
Immunotherapy of melanoma
Kee, D., & McArthur, G. A. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.014 · Cited by 26
A Novel Etiology of Hypophysitis
Fernandes, S., Varlamov, E. V., McCartney, S., & Fleseriu, M. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.002 · Cited by 25
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
Kejamurthy, P., & Devi, K. T. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02267-4 · Cited by 28
Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma
Billaud, E. M. F., Rbah‐Vidal, L., Vidal, A., Besse, S., Tarrit, S., Askienazy, S., Maisonial‐Besset, A., Moins, N., Madelmont, J., Miot-Noirault, E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400877v · Cited by 25
Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches
Motofei, I. G. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000573 · Cited by 25
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up
Caraglia, M., Correale, P., Giannicola, R., Staropoli, N., Botta, C., Pastina, P., Nesci, A., Caporlingua, N., Francini, E., Ridolfi, L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01102 · Cited by 25
Inhibitory costimulation and anti-tumor immunity
Martín‐Orozco, N., & Dong, C. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.003 · Cited by 26
Local therapy for cancer therapy-associated uveitis: a case series and review of the literature
Venkat, A., Arepalli, S., Sharma, S. K., Karthik, N., Lowder, C. Y., Ehlers, J. P., Singh, A. D., Goshe, J. M., & Srivastava, S. K. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-314403 · Cited by 24
Melanoma immunotherapy dominates the field
Diamantopoulos, P. T., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.32 · Cited by 25
Current State of Vaccine Therapies in Non–Small-Cell Lung Cancer
Romero, P. J. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.s.005 · Cited by 25
Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers
Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23
Immune alterations in malignant melanoma and current immunotherapy concepts
Shimanovsky, A., Jethava, A., & Dasanu, C. A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.827658 · Cited by 24
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Sachpekidis, C., Kopp‐Schneider, A., Pan, L., Papamichail, D., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05137-7 · Cited by 24
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
Serna-Higuita, L. M., Amaral, T. M. S., Forschner, A., Leiter, U., Flatz, L., Seeber, O., Thomas, I., Garbe, C., Eigentler, T., & Martus, P. (2021) · Cancers · doi:10.3390/cancers13236141 · Cited by 23
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Machairas, N., Tsilimigras, D. I., & Pawlik, T. M. (2022) · Cancers · doi:10.3390/cancers14082018 · Cited by 24
Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies
Chang, S. T., Menias, C. O., Lubner, M. G., Mellnick, V. M., Hara, A. K., & Desser, T. S. (2017) · Radiographics · doi:10.1148/rg.2017160162 · Cited by 23
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)
Hwang, S. J. E., & Fernández‐Peñas, P. (2017) · Current problems in dermatology · doi:10.1159/000478081 · Cited by 23
p110δ PI3K as a therapeutic target of solid tumours
Xenou, L., & Papakonstanti, E. A. (2020) · Clinical Science · doi:10.1042/cs20190772 · Cited by 23
Immune-Related Adverse Events: Pneumonitis
Jain, A., Shannon, V. R., & Sheshadri, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_6 · Cited by 23
Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab
Ajgal, Z. C., Goulvestre, C., Zaibet, S., Arrondeau, J., Bretagne, M., Peyromaure, M., Batteux, F., Alexandre, J., Goldwasser, F., & Huillard, O. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.04.002 · Cited by 22
Novel therapeutics for melanoma
Seetharamu, N., Ott, P. A., & Pavlick, A. C. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.40 · Cited by 22
Myasthenia Gravis Induced by Nivolumab in Patients with Non-Small-Cell Lung Cancer: A Case Report and Literature Review
Hasegawa, Y., Kawai, S., Ota, T., Tsukuda, H., & Fukuoka, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0043 · Cited by 23
The challenges of checkpoint inhibition in the treatment of multiple myeloma
Paul, B. A., Kang, S., Zheng, Z., & Kang, Y. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.10.003 · Cited by 22
Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors
Lei, M. M., Michael, A., Patel, S. V., & Wang, D. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219829813 · Cited by 21
Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program
Bisschop, C., Wind, T. T., Blank, C. U., Koornstra, R. H. T., Kapiteijn, E., van den Eertwegh, A. J. M., de Groot, J. W. B., Jalving, M., & Hospers, G. A. P. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000271 · Cited by 22
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
Vitale, M. G., Pipitone, S., Venturelli, M., Baldessari, C., Porta, C., Iannuzzi, F., Basso, U., Scagliarini, S., Zucali, P. A., Galli, L., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.05.010 · Cited by 22
Anticorps anti-CTLA-4
Robert, C., & Mateus, C. (2011) · médecine/sciences · doi:10.1051/medsci/20112710013 · Cited by 22
Novel Therapeutics for The Treatment of Metastatic Melanoma
Mansfield, A. S., & Markovic, S. N. (2009) · Future Oncology · doi:10.2217/fon.09.15 · Cited by 22
Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
Weide, B., Di Giacomo, A. M., Fonsatti, E., & Zitvogel, L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.016 · Cited by 21
Use of ipilimumab in the treatment of melanoma
Jeter, J., & Acharya, U. H. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s45884 · Cited by 21
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives
Marinelli, D., Giusti, R., Mazzotta, M., Filetti, M., Krasniqi, E., Pizzuti, L., Landi, L. M., Tomao, F., Cappuzzo, F., Ciliberto, G., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103176 · Cited by 18
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
de la Bruyère, C. L., Souquet, P.-J., Dalle, S., Corbaux, P., Boespflug, A. M., Duruisseaux, M., Kiakouama-Maleka, L., Reverdy, T., Maugeais, M., Şahin, G., et al. (2021) · Cancers · doi:10.3390/cancers13102365 · Cited by 21
Stromal Cells Underlining the Paths From Autoimmunity, Inflammation to Cancer With Roles Beyond Structural and Nutritional Support
Honan, A. M., & Chen, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.658984 · Cited by 21
Regional lymphatic immunity in melanoma
Grotz, T. E., Mansfield, A. S., Jakub, J. W., & Markovic, S. N. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834e1f33 · Cited by 20
Immunologic functions as prognostic indicators in melanoma
Bouwhuis, M. G., ten Hagen, T. L. M., & Eggermont, A. M. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.004 · Cited by 21
Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 21
Proposed mechanisms of action for prostate cancer vaccines
Geary, S. M., Lemke-Miltner, C. D., Lubaroff, D. M., & Salem, A. K. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.8 · Cited by 23
An Update on Malignant Melanoma Vaccine Research
Ralph, S. J. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708030-00001 · Cited by 20
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management
Movva, S., & Verschraegen, C. F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802643347 · Cited by 21
Improving T cell therapy for cancer
Foster, A. E., & Rooney, C. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.215 · Cited by 22
No Correlation Between Clinical Response to CTLA-4 Blockade and Presence of NY-ESO-1 Antibody in Patients With Metastatic Melanoma
Goff, S. L., Robbins, P. F., El‐Gamil, M., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181affbf0 · Cited by 21
Self-citation
Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database
Quiruz, L. A., Yavari, N., Kikani, B., Gupta, A., Wai, K. M., Kossler, A. L., Ludwig, C. A., Koo, E., Rahimy, E., & Mruthyunjaya, P. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.08.044 · Cited by 21
Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma
King, J., & Nathan, P. (2014) · Future Oncology · doi:10.2217/fon.14.89 · Cited by 21
Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
Wiater, K., Świtaj, T., Mackiewicz, J., Kalinka‐Warzocha, E., Wojtukiewicz, M. Z., Szambora, P., Falkowski, S., Rogowski, W., Mackiewicz, A. A., & Rutkowski, P. L. (2013) · Współczesna Onkologia · doi:10.5114/wo.2013.35785 · Cited by 20
Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis
Xu, Y., Jiang, Z., Kuang, X., Chen, X., & Liu, H. (2022) · Journal of Medical Internet Research · doi:10.2196/32728 · Cited by 20
Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide
Rubin, K. M. (2012) · Clinical journal of oncology nursing · doi:10.1188/12.cjon.e69-e75 · Cited by 20
Biomarkers for the Development of Cancer Vaccines
Copier, J. P., Whelan, M., & Dalgleish, A. G. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256210 · Cited by 20
Endocrine dysfunction following immune checkpoint inhibitor therapy
Konda, B., Nabhan, F. A., & Shah, M. H. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000357 · Cited by 20
DNA Vaccines Against Cancer
Stan, R., Wolchok, J. D., & Cohen, A. D. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.02.004 · Cited by 20
Melanoma Vaccines
Chapman, P. B. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.09.013 · Cited by 20
Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
Les, Í., Pérez-Francisco, I., Cabero, M., Sánchez, C., Hidalgo, M., Teijeira, L., Arrazubi, V., Domínguez, S., Anaut, P., Eguiluz, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894550 · Cited by 19
Impact of a Recombinant Fowlpox Vaccine on the Efficacy of Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes in a Patient With Metastatic Melanoma
Smith, F. O., Klapper, J. A., Wunderlich, J. R., Rosenberg, S. A., & Dudley, M. E. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b36b69 · Cited by 19
Self-citation
Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen
Bridle, B. W., Li, J., Jiang, S., Chang, R. Y., Lichty, B. D., Bramson, J. L., & Wan, Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901447 · Cited by 19
Ipilimumab in anti-PD1 refractory metastatic melanoma
Jacobsoone-Ulrich, A., Jamme, P., Alkeraye, S., Dzwiniel, V., Faure, E., Templier, C., & Mortier, L. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000221 · Cited by 19
Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy
Arranz‐Nicolás, J., & Mérida, I. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100663 · Cited by 19
Treatment of Melanoma and Nonmelanoma Skin Cancer
Rass, K., & Tilgen, W. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77574-6_23 · Cited by 19
Targeting metastatic melanoma
Poust, J. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080461 · Cited by 19
Immune modulation by dendritic-cell-based cancer vaccines
Kumar, C., Kohli, S., Bapsy, P. P., Vaid, A. K., Jain, M. M., Attili, V. S. S., & Sharan, B. (2017) · Journal of Biosciences · doi:10.1007/s12038-017-9665-x · Cited by 19
Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults
Rotz, S. J., Ware, R. E., & Kumar, A. R. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27260 · Cited by 18
Skin Reactions to Immune Checkpoint Inhibitors
Patel, A. B., & Pacha, O. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_5 · Cited by 18
Monoclonal Antibody Therapy for Cancer
Rader, C. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_3 · Cited by 19
Immune checkpoint blockade for cancer therapy: current progress and perspectives
Ye, H., Liao, W., Pan, J., Shi, Y. P., & Wang, Q. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300492 · Cited by 23
Delayed Dermatologic Hypersensitivity Reaction Secondary to Ipilimumab
Ludlow, S. P., & Kay, N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000076 · Cited by 18
Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma
Monge, C., Xie, C., Steinberg, S. M., & Greten, T. F. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s311496 · Cited by 17
Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
Hao, Y., & Cook, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806043 · Cited by 21
Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models
Persson, J., Beyer, I., Yumul, R., Li, Z.-Y., Kiem, H., Roffler, S. R., & Lieber, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022303 · Cited by 20
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Olin, M. R., Pluhar, G. E., Andersen, B. M., Shaver, R. L., Waldron, N. N., & Moertel, C. L. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014011577 · Cited by 18
A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy
Howard, S. A. H., Krajewski, K. M., Jagannathan, J. P., Braschi‐Amirfarzan, M., Tirumani, S. H., Shinagare, A. B., & Ramaiya, N. H. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15480 · Cited by 18
Skin Reactions to Immune Checkpoint Inhibitors
Patel, A. B., & Pacha, O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_9 · Cited by 18
Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
Barham, W. J., Guo, R. R., Park, S. S., Herrmann, J., Dong, H., & Yan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561083 · Cited by 18

Authors: Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Restifo, N. P., Haworth, L. R., Levy, C., Mavroukakis, S. A., Nichol, G., Yellin, M. J., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
ORCID: Phan, Giao Q.
Maker, Ajay V.
Robinson, Michael R.
Quezado, Martha M.
Yang, James C.
Sherry, Richard M.
Topalian, Suzanne L.
Kammula, Udai S.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Yellin, Michael J.
Rosenberg, Steven A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 6043-6053
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.06.205
PMC: PMC1473965
OpenAlex: W2151507811
Cited by: 1,012
References: 44
Citations by year: 2026: 6 · 2025: 15 · 2024: 18 · 2023: 17 · 2022: 31 · 2021: 45 · 2020: 81 · 2019: 46 · 2018: 45 · 2017: 55 · 2016: 60 · 2015: 64 · 2014: 49 · 2013: 63 · 2012: 43
FWCI: 30.93
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: metastatic melanoma, anti-CTLA-4 monoclonal antibody, CTLA-4 blockade, autoimmunity, autoimmune toxicity, tumor regression, peptide vaccination, gp100, dosing regimen, immune checkpoint inhibitors, objective response rate
MeSH terms: Adult, Aged, Antigens, Differentiation, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents, Injections, Intravenous, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Autoimmunity, Antigens, CD, Treatment Outcome, Cancer Vaccines, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks